ribavirin has been researched along with Obesity in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (55.00) | 29.6817 |
| 2010's | 9 (45.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cornberg, M; Deterding, K; Kirschner, J; Manns, MP; Mix, C; Port, K; Schlevogt, B; Siederdissen, CHZ; Sollik, L; Wedemeyer, H | 1 |
| Berger, F; Boesecke, C; Buendgens, L; Christensen, S; Hüppe, D; Ingiliz, P; Lutz, T; Mauss, S; Schewe, K; Simon, KG; Tacke, F | 1 |
| Armienta-Sarabia, R; Cordero-Pérez, P; Hernández-Gómez, ME; Malé-Velázquez, R; Marín-López, E; Muñoz-Espinosa, LE; Núñez-Camarena, Jde J; Olivera-Martínez, MA; Sánchez-Avila, JF; Torres-González, L | 1 |
| Aldámiz-Echevarria, T; Berenguer, J; Carrero, A; Diez, C; García-Alvarez, M; García-Broncano, P; Guzmán-Fulgencio, M; Jiménez-Sousa, MA; Pineda-Tenor, D; Resino, S; Tejerina, F; Vázquez-Morón, S | 1 |
| Anzai, K; Eguchi, Y; Fujimoto, K; Iwane, S; Kawaguchi, Y; Kawazoe, S; Kuwashiro, T; Mizuta, T; Nakashita, S; Oeda, S; Otsuka, T; Oza, N; Ozaki, I; Takahashi, H | 1 |
| Abd-Ellah, MF; Gad, MA; Helal, GK; Mahgoup, EM | 1 |
| Fehér, J; Hagymási, K | 1 |
| Bressler, B; Grippo, JF; Heathcote, EJ; Wang, K | 1 |
| Abdurakhmanov, D; Bakulin, I; Cheinquer, H; Geyvandova, N; Harrison, SA; McKenna, M; Morozov, V; Rabbia, M; Reddy, KR; Rodriguez-Torres, M; Shiffman, ML; Silva, GF; Stanciu, C; Thommes, JA | 1 |
| Ghany, MG; Seeff, LB | 1 |
| Alsiö, Å; Askarieh, G; Buhl, MR; Christensen, PB; Färkkilä, M; Haagmans, BL; Hellstrand, K; Lagging, M; Langeland, N; Mørch, K; Nasic, S; Norkrans, G; Pedersen, C; Rembeck, K; Westin, J | 1 |
| Larrey, D | 1 |
| Asselah, T | 1 |
| Bressler, BL; Guindi, M; Heathcote, J; Tomlinson, G | 1 |
| Clouston, AD; Jonsson, JR; Lipka, GM; Powell, EE; Purdie, DM; Richardson, MM; Walsh, MJ | 1 |
| Ariello, M; Conca, P; Sorrentino, P; Tarantino, G | 1 |
| Bini, EJ; Bräu, N; Cheung, RC; Currie, SL; Ho, SB; Hu, KQ; Jeffers, L; McCracken, JD; Morgan, T; Schmidt, WN; Shen, H; Wright, TL | 1 |
| Almasio, PL; Amato, M; Craxí, A; De Lisi, S; Di Marco, V; Ferraro, D; Giordano, C; Lo Iacono, O; Mineo, C; Petta, S; Rodolico, V; Venezia, G | 1 |
| Brandt, LR; Cua, IH; George, J; Hui, J; Kench, JG; Negro, F; Poustchi, H | 1 |
3 review(s) available for ribavirin and Obesity
| Article | Year |
|---|---|
Management of untreated and nonresponder patients with chronic hepatitis C.
Topics: Alcohol Drinking; Antiviral Agents; Biopsy; Decision Making; Deoxycytidine; Disease Management; Disease Progression; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Obesity; Polyethylene Glycols; Practice Patterns, Physicians'; Recombinant Proteins; Retreatment; Ribavirin; RNA, Viral; Treatment Failure; Viral Load; Virus Replication | 2010 |
[Chronic hepatitis C: apart from antiviral treatment what other measures should be recommended?].
Topics: Adult; Alcoholism; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Iron Deficiencies; Liver Transplantation; Male; Obesity; Patient Education as Topic; Ribavirin; Risk Factors; Smoking; Smoking Prevention; Time Factors | 2002 |
[Chronic hepatitis C: what to do if the first treatment failed?].
Topics: Amantadine; Animals; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Ethanol; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Mice; Mice, Transgenic; Multicenter Studies as Topic; Obesity; Randomized Controlled Trials as Topic; Recurrence; Ribavirin; Risk Factors; Smoking; Time Factors | 2002 |
6 trial(s) available for ribavirin and Obesity
| Article | Year |
|---|---|
Impact of Body Weight Reduction via Diet and Exercise on the Anti-Viral Effects of Pegylated Interferon Plus Ribavirin in Chronic Hepatitis C Patients with Insulin Resistance: A Randomized Controlled Pilot Trial.
Topics: Adult; Antiviral Agents; Body Weight; Diet; Directive Counseling; Drug Therapy, Combination; Exercise; Female; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon-alpha; Male; Middle Aged; Obesity; Pilot Projects; Prospective Studies; Ribavirin; Treatment Outcome; Viral Load; Weight Loss | 2015 |
Coadministration of ezetimibe with pegylated interferon plus ribavirin could improve early virological response in chronic hepatitis C obese Egyptian patients.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Egypt; Ezetimibe; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Obesity; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Single-Blind Method; Time Factors; Treatment Outcome; Viral Load; Virus Internalization | 2016 |
Pharmacokinetics and response of obese patients with chronic hepatitis C treated with different doses of PEG-IFN alpha-2a (40KD) (PEGASYS).
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Obesity; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult | 2009 |
Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads.
Topics: Adult; Antiviral Agents; Body Weight; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Obesity; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Viral Load | 2010 |
Impact of obesity on the bioavailability of peginterferon-α2a and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3.
Topics: Adult; Antiviral Agents; Biological Availability; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Obesity; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2012 |
Clinical implications of hepatic steatosis in patients with chronic hepatitis C: a multicenter study of U.S. veterans.
Topics: Adult; Aged; Antiviral Agents; Body Mass Index; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Hospitals, Veterans; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Obesity; Prevalence; Prospective Studies; Recombinant Proteins; Ribavirin; Risk Factors; Severity of Illness Index; Treatment Outcome; United States | 2007 |
11 other study(ies) available for ribavirin and Obesity
| Article | Year |
|---|---|
Interferon-free cure of chronic Hepatitis C is associated with weight gain during long-term follow-up.
Topics: Adult; Aged; Antimetabolites; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Middle Aged; Obesity; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome; Weight Gain | 2017 |
Risk factors for remaining liver injury in patients with virological elimination of chronic hepatitis C.
Topics: Alanine Transaminase; Antiviral Agents; Fatty Liver; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Obesity; Prospective Studies; Ribavirin; Risk Factors; Sex Factors | 2019 |
Re-treatment with highly purified nIFNα in Mexican nonresponder patients with chronic genotype 1 hepatitis C.
Topics: Antiviral Agents; Asthenia; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Obesity; Pilot Projects; Prospective Studies; Recombinant Proteins; Retreatment; Ribavirin; Viral Load | 2013 |
FTO rs9939609 polymorphism is associated with metabolic disturbances and response to HCV therapy in HIV/HCV-coinfected patients.
Topics: Adult; Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Antiviral Agents; Body Mass Index; Coinfection; Cross-Sectional Studies; Female; Genetic Predisposition to Disease; Genotype; Hepatitis C, Chronic; HIV Infections; Humans; Insulin Resistance; Male; Metabolic Syndrome; Middle Aged; Obesity; Odds Ratio; Polymorphism, Single Nucleotide; Proteins; Ribavirin | 2014 |
[Influence of weight reduction on the effectiveness of combined peginterferon and ribavirin treatment in chronic HCV hepatitis].
Topics: Amantadine; Antioxidants; Antiviral Agents; Drug Therapy, Combination; Fatty Liver; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Obesity; Polyethylene Glycols; Protective Agents; Recombinant Proteins; Ribavirin; Silymarin; Treatment Outcome; Weight Loss | 2008 |
High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C.
Topics: Adult; Antiviral Agents; Body Mass Index; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Obesity; Retrospective Studies; Ribavirin; Risk Factors; Treatment Failure | 2003 |
[Hepatitis C infection. Overweight virus carriers are more difficult to cure].
Topics: Antiviral Agents; Biological Availability; Body Weight; Carrier State; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Metabolic Clearance Rate; Obesity; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2004 |
Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunohistochemistry; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Obesity; Phosphoenolpyruvate Carboxykinase (GTP); Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Signal Transduction; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins; Treatment Outcome | 2006 |
Metabolic factors involved in the therapeutic response of patients with hepatitis C virus-related chronic hepatitis.
Topics: Antiviral Agents; Biopsy; Body Mass Index; Case-Control Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Obesity; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Risk Factors; Treatment Failure | 2006 |
The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C.
Topics: Adipocytes; Adult; Antiviral Agents; Fatty Liver; Female; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Intra-Abdominal Fat; Liver Cirrhosis; Male; Middle Aged; Obesity; Recombinant Proteins; Ribavirin | 2007 |
Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3.
Topics: Adult; Aged; Antiviral Agents; Blood Glucose; Body Mass Index; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin; Insulin Resistance; Interferons; Liver; Liver Cirrhosis; Liver Function Tests; Logistic Models; Male; Middle Aged; Obesity; Ribavirin; Treatment Failure; Treatment Outcome | 2008 |